Skip to main content
Evidence Snapshot

Epidermal growth factor receptor

CHEMBL203 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T22:27:30Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL203
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Epidermal growth factor receptor as ChEMBL target CHEMBL203, mapped to UniProt P00533. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Epidermal growth factor receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-12
ChEMBL target ID
CHEMBL203
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-12
www.ebi.ac.uk
UniProt accession
P00533
Epidermal growth factor receptor
UniProt accession via ChEMBL component mapping As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-12
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Epidermal growth factor receptor matters

As of 2026-09-12

Epidermal growth factor receptor is reviewed as Epidermal growth factor receptor (UniProt P00533); Epidermal growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 47 linked drugs keep this evidence frame grounded.; the current evidence base includes 101 approved drugs, 18692 compounds, and 5782 assays, with lead potency reaching pChEMBL 11.0.

Disease context
neoplasm

Epidermal growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 47 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AC-480, AMIVANTAMAB, AUMOLERTINIB.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AC-480, AMIVANTAMAB, AUMOLERTINIB, AV-412. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 47 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 101 approved drugs, 18692 compounds, and 5782 assays for this target. The dominant activity type is IC50. CHEMBL4650319 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4650319 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
101 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Epidermal growth factor receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00533, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

18692
Total Compounds
5782
Total Assays
101
Approved Drugs
IC50: 25711.0, KI: 2054.0, EC50: 429.0, KD: 1888.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4650319
 11.0 IC50 Approved
No preferred name
CHEMBL176582
 11.0 IC50 —
No preferred name
CHEMBL5790648
 10.8 IC50 —
No preferred name
CHEMBL5746224
 10.8 IC50 —
No preferred name
CHEMBL5997498
 10.7 IC50 —

Approved Drugs

Structure Compound First Approval
LAZERTINIB
CHEMBL4558324
 2024
MOBOCERTINIB
CHEMBL4650319
 2021
TUCATINIB
CHEMBL3989868
 2020
FEDRATINIB
CHEMBL1287853
 2019
ZANUBRUTINIB
CHEMBL3936761
 2019
DACOMITINIB
CHEMBL2105719
 2018
DACOMITINIB ANHYDROUS
CHEMBL2110732
 2018
LORLATINIB
CHEMBL3286830
 2018
MIDOSTAURIN
CHEMBL608533
 2017
NERATINIB
CHEMBL180022
 2017
ACALABRUTINIB
CHEMBL3707348
 2017
BRIGATINIB
CHEMBL3545311
 2017
OLMUTINIB
CHEMBL3786343
 2016
OSIMERTINIB
CHEMBL3353410
 2015
CERITINIB
CHEMBL2403108
 2014
AFATINIB
CHEMBL1173655
 2013
AFATINIB DIMALEATE
CHEMBL2105712
 2013
IBRUTINIB
CHEMBL1873475
 2013
BOSUTINIB
CHEMBL288441
 2012
CABOZANTINIB
CHEMBL2105717
 2012
VANDETANIB
CHEMBL24828
 2011
CRIZOTINIB
CHEMBL601719
 2011
VEMURAFENIB
CHEMBL1229517
 2011
LAPATINIB
CHEMBL554
 2007
LAPATINIB DITOSYLATE
CHEMBL1201179
 2007
DASATINIB
CHEMBL5416410
 2006
SUNITINIB
CHEMBL535
 2006
VORINOSTAT
CHEMBL98
 2006
DASATINIB ANHYDROUS
CHEMBL1421
 2006
SORAFENIB
CHEMBL1336
 2005
ERLOTINIB
CHEMBL553
 2004
ERLOTINIB HYDROCHLORIDE
CHEMBL1079742
 2004
GEFITINIB
CHEMBL939
 2003
IMATINIB
CHEMBL941
 2001
DOCETAXEL
CHEMBL3545252
 1995
EBASTINE
CHEMBL305660
 1990
GENTIAN VIOLET
CHEMBL64894
 1982
SULOCTIDIL
CHEMBL404849
 1979
HEXACHLOROPHENE
CHEMBL496
 1949
BITHIONOL
CHEMBL290106
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T22:27:30Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL203